Lorlatinib: First Global Approval
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Based on results from a phase I/II trial, lorlatinib received approval in Japan in September 2018 and in the USA in November 2018 for the treatment of ALK-positive NSCLC. This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 7.Pfizer. Lorlatinib (Lorbrena®): Japanese prescribing Information [English translation]. 2018. https://www.pmda.go.jp. Accessed 26 Nov 2018.
- 8.Pfizer. Lorbrena® (lorlatinib): US rescribing information 2018. https://www.fda.gov. Accessed 26 Nov 2018.
- 9.Pfizer. Pfizer's next-generation ALK/ROS1 inhibitor, lorlatinib, granted breakthrough therapy designation from FDA for ALK-positive metastatic non-small cell lung cancer [media release]. http://www.pfizer.com. Accessed 26 Nov 2018.
- 10.Pfizer. U.S., EU and Japan health authorities accept regulatory submissions for review of Pfizer’s third-generation ALK inhibitor lorlatinib [media release]. http://www.pfizer.com. Accessed 26 Nov 2018.
- 11.Government of Canada. Drug and health product submissions under review (SUR). 2018. https://www.canada.ca. Accessed 20 Nov 2018.
- 17.Ou S, Shaw A, Riely G, et al. Clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6 [abstract no. OA02.03 ]. J Thorac Oncol. 2018;13(10 Suppl):S322–S3.Google Scholar
- 18.Shaw AT, Martini JF, Besse B, et al. Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations [abstract no. CT044]. Cancer Res. 2018;78(13 Suppl).Google Scholar
- 19.Shaw A, Bauer T, Takahashi T, et al. First-line lorlatinib versus crizotinib for advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer [abstract no. P1.13-06]. J Thorac Oncol. 2018;13(10 Suppl):S584.Google Scholar